New pivotal Phase III trial (PRECiSE 1) data presented today at Digestive Disease Week 2006 (DDW) in Los Angeles have demonstrated that when compared with placebo, a significantly greater proportion of moderate to severe Crohn's disease patients achieved clinical response with subcutaneous once-monthly CIMZIA™ (certolizumab pegol, CDP870), a new type of anti-Tumor Necrosis Factor (anti-TNF) therapy.
